AstraZeneca Plans Direct NYSE Listing While Retaining UK Base

AstraZeneca announced plans to directly list its ordinary shares on the New York Stock Exchange, replacing its existing US listing of American Depository Receipts on Nasdaq, while maintaining its London Stock Exchange and Nasdaq Stockholm listings as well as its UK headquarters and tax residency. This harmonization of its listing structure aims to create a global listing for global investors, broadening its investor base and enhancing access to capital markets, particularly in the US, which hosts the largest and most liquid public markets. Despite speculation about shifting its primary listing away from London, AstraZeneca reaffirmed its commitment to the UK market, signaling confidence in its UK base. The move supports AstraZeneca's long-term strategy for sustainable growth and aims to make the company's shares more attractive and accessible to a diverse group of global investors. The company's strong financial performance, robust pipeline, and strategic initiatives contribute to a positive outlook despite some market challenges. AstraZeneca remains a science-led biopharmaceutical company headquartered in Cambridge, UK, with a global presence and diversified portfolio.